AmerisourceBergen Kicks Off Strategic Relationship with Civica
AmerisourceBergen will serve as Civica, Inc.’s exclusive distribution partner, providing supply chain support for Civica’s products and working to ensure that Civica’s crucial products reach its members across the country efficiently, reliably and securely. The partnership aims to accelerate mutual efforts to ensure the stability of supply of essential generic medicines nationwide.
Civica Welcomes Ypsomed as Injection Pen Partner for Its Affordable Insulin Initiative
“As a renowned injection device specialist with over 35 years’ experience, Ypsomed will help Civica make self-administered care more affordable for Americans living with diabetes,” said Ned McCoy, President and Chief Executive Officer of Civica. “Civica will deliver affordable, high-quality insulin, in the best pen platform, utilizing our new, state of the art manufacturing technology in Petersburg, Virginia.”
Utah-based Nonprofit Set to Open $140M Insulin Plant in Petersburg
Petersburg is at the center of a nonprofit’s push to lower sky-high insulin costs. Utah-based Civica Rx is in the final stages of building a $140 million insulin production plant in the city and expects to begin retail sales in 2024.
California Selects Civica Rx as Its Insulin Manufacturing Partner
California’s partnership with Civica is a game changer,” said California Governor Gavin Newsom, announcing the state’s choice of Civica to manufacture insulins for the State of California’s CalRx Biosimilar Insulin Initiative. “We are proud to be working with Civica to bring true price competition into the insulin drug market and ease the financial burden for Californians living with diabetes.”
CivicaScript, SortPak Partner to Package & Deliver Medicines to Maximize Patient Convenience, Compliance & Savings
CivicaScript, which is dedicated to bringing lower-cost generic medicines to U.S. consumers, and SortPak, which delivers pre-sorted medications to patients at no extra cost to patients or health plans, are partnering to provide CivicaScript medicines in packaging designed to maximize patient convenience, savings and medication compliance.
What Spurred Lilly, Novo and Sanofi to Slash Insulin Prices? Expert Gives Her Take
The price cuts can be explained by a mix of factors, Leemore Dafny, Ph.D., wrote in a new analysis for The New England Journal of Medicine, titled “Falling Insulin Prices – What Just Happened?” One: The market is awaiting the entry of certain manufacturers that “don’t benefit from high prices.” Two: Government regulations are making it “costlier” for insulin manufacturers to keep charging their prior prices. Three: Public shaming.
CivicaRx Disrupts Out of Control Prescription Medication Pricing
Civica believes its model of rallying others to work together to ensure a reliable supply of fairly priced medicines is one that the wider pharmaceutical industry can ultimately support.